Emergency patients treated with naproxen and placebo had outcomes as good as or better than patients treated with naproxen and diazepam (Valium, Roche) for acute lower back pain, according to the results of a double-blind, randomized clinical study published in the Annals of Emergency Medicine.
“Our study contributes to the growing body of literature indicating that, in general, most medications do not improve acute lower back pain,” said lead author Benjamin Friedman, MD, MS, of the Albert Einstein College of Medicine/Montefiore Health System in Bronx, New York. “One week after being discharged from the emergency department [ED], lower back pain patients had improved equally, regardless of whether they were treated with naproxen and diazepam or naproxen and placebo. By three months after visiting the emergency department, most patients had recovered completely, regardless of what treatment they received.”
Researchers randomly assigned 114 patients who came to the ED with new-onset lower back pain to two treatment groups. One group was treated with a combination of the nonsteroidal anti-inflammatory drug naproxen and diazepam (a benzodiazepine derivative), and the other group was treated with a combination of naproxen and placebo. One week after visiting the ED, the diazepam group improved by 11 points on the Roland Morris Disability Questionnaire, as did the placebo group.
After one week, 31.5% of the diazepam-treated patients reported moderate or severe lower back pain, whereas 21.8% of the placebo-treated patients did. At three months, 12% of the diazepam group reported moderate or severe lower back pain, whereas 9% of the placebo group did. The differences were not considered clinically or statistically significant.
“Millions of patients come to the [emergency department] every year seeking relief for back pain, which can be debilitating,” Friedman said. “Unfortunately, we have yet to come up with the silver bullet in pill form that helps them. If anything, we may be overmedicating these patients.”
Source: American College of Emergency Physicians(link is external); February 16, 2017.
Avedis Donabedian, MD
The measures most often used today to assess care quality are process measures. Actual outcomes, of course, are harder to measure than whether a certain action has been taken—checking the feet of a patient with diabetes, for example. But many experts don’t think process measures get at the heart of quality.
FiercePharma has compiled a list of the top 15 cancer medications that are expected to dominate the oncology market in 2022.
The problem, say hospitals and some analysts, is that rating hospital quality is not so straightforward. How a hospital delivers care is multifactorial and complex, they argue, so trying to cram that into a single score is misleading and can end up like rating a restaurant on its parking.
Matthew Hamilton, MD
Men’s health care changed dramatically after the FDA approved Pfizer’s blue, diamond-shaped Viagra. Suddenly men were interested in seeing their doctors if for only one reason. Now, with restrictions on what some call a lifestyle drug, other health problems go uncharted.
Joint venture plans are starting to demonstrate their ability to implement clinical management and financial management reforms. A JV health plan replaces the offloading of financial risk by health plans to ill-equipped providers with an executive-level cost management committee stated jointly by the hospital and payer.
For several days, a middle-aged woman who claimed to be a doctor in training roamed the halls of Brigham and Women’s Hospital in Boston, dressed in scrubs, asking questions at a lecture, attending patient rounds, and observing surgical procedures, according to a report in the Boston Globe
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.